MindWalk (HYFT) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed MindWalk (HYFT) over the past year, losing 5.4% versus a loss of 23.5%. Over five years, HYFT leads with a -78.3% price change compared with -96.9% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($70.6 million vs $70.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYFT | VRCA |
|---|---|---|
| Share price | $1.50 | $4.11 |
| Market cap | $70.43M | $70.60M |
| 1-day change | +4.55% | -1.67% |
| YTD return | -21.43% | -49.70% |
| 1-year return | -23.53% | -5.43% |
| 5-year return | -78.27% | -96.87% |
| EPS (TTM) | $-0.26 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.99 | $9.82 |
| 52-week low | $0.99 | $3.28 |
| Distance from 52-week high | -50.00% | -58.15% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +189.63% | +236.50% |
| Average volume | 229.74K | 62.56K |
| Shares outstanding | 47.11M | 17.18M |
| Employees | 74 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed HYFT by 18.1 percentage points over the past year.
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
HYFT vs VRCA FAQ
Which is bigger, MindWalk or Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $70.60M compared with $70.43M for MindWalk (HYFT).
Which stock has performed better over the past year, HYFT or VRCA?
VRCA returned -5.43% over the past 12 months, compared with -23.53% for HYFT (price return, excluding dividends). Past performance does not predict future results.
Are MindWalk and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.